Merck partners with Pfizer, Amgen and Incyte to study promising cancer drug

As it pushes forward with plans to win approval for a potentially groundbreaking new cancer therapy, Merck & Co, is collaborating with competitors Pfizer, Amgen and Incyte to study how its drug works in combination with other companies’ medicines.